OWL-LABS
23.6.2021 01:03:07 CEST | Business Wire | Press release
Research conducted by Owl Labs , which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%).
As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders anticipate that Covid-19 will continue to impact the running of their business for up to six months. French business leaders are the most optimistic with one in five (20%) believing Covid-19 would only impact the running of their office for the next three months or less. However, the majority believe that remote and hybrid working has positively impacted their business, with the majority stating it had impacted employee wellbeing (52%) and business costs (50%) positively.
With a growing desire to support employees' partial return-to-office, one in four EU organisations (24%) are now planning to enforce ‘vaccine passports’ and only allow those who have been vaccinated into the office. Germany is the most cautious with 31% of business leaders insisting on Covid-19 vaccines, while 23% of business leaders in the UK, 21% in the Nordics and 19% in France intend to enforce vaccines. Additionally, over a third (38%) of EU business leaders are considering providing onsite Covid-19 testing facilities to encourage employees to return to work, with French and German organisations most likely to provide onsite testing facilities at 42% and 43% respectively.
European organisations are already planning ahead to a post-pandemic work environment, with the majority of business leaders (63%) aiming to maintain the same amount of office space, even with the rise of hybrid work. Just 11% are planning to get rid of their offices entirely (rising to 14% in the Nordics). When it comes to hiring, one-third of EU organisations (32%) plan to hire employees who can work remotely, based on skill, rather than their proximity to an office. In a move that may not be welcomed by employees, 29% of business leaders plan to use productivity apps to monitor activity of remote employees. This rises steeply in Germany, where 37% of business leaders plan on utilising productivity and activity monitoring of remote employees, compared to just 22% of Nordic business leaders.
As businesses move to hybrid and flexible working, technology plays a crucial role in enabling this shift. As a result, the majority (93%) of European organisations are putting workplace policies and infrastructure in place to prepare for a post-pandemic workplace. This includes nearly half (42%) of European businesses investing in new tech and solutions to support a hybrid workforce. The UK leads the tech charge with 43% investing in communications tools (such as Slack, Zoom, and Meeting Owl conference cameras) compared to 28% in the Nordics, 36% in France and 38% in Germany. The primary activities companies are carrying out to prepare their workplaces now and post-pandemic are:
○ Investing in communication tools and technology (Slack, Zoom, conference cameras, Meeting Owls, etc.) (36%)
○ Continued social-distancing measures for employees in the office (35%)
○ Providing at-home and in-office equipment for employees so they can easily work from both locations (33%)
Frank Weishaupt, CEO of Owl Labs says, “It’s encouraging to see business leaders across Europe embrace hybrid work post-pandemic. As organisations have adapted to working remotely, they’ve seen the benefits. The ability to hire remote teams from anywhere, leverage new technologies whilst saving on costs. We know that technology will continue to play a key role in supporting this permanent shift to hybrid work, and businesses that will be successful will create the infrastructure and workplace policies that enable their employees to maintain high levels of creativity and collaboration, wherever they dial-in from.”
---ends---
Methodology:
* Business Leaders refer to C-suite executives, heads of departments, HR managers and general managers
**The Nordics refers to Sweden, Finland, Norway & Denmark
About Owl Labs
Owl Labs is a collaborative technology company dedicated to creating a better workplace and learning experience for today's hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl Pro , features a wifi-enabled, portable 360° camera, mic, and speaker with proprietary AI technology that automatically focuses on who is speaking using audio and visual cues. The company is a recipient of TIME’s Best Inventions of 2020 and is dedicated to providing collaborative and productivity solutions for organizations to stay connected to their remote employees and educators to stay connected to their remote students, regardless of location. Learn more at www.owllabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
